Ardelyx slips as commercial chief departs [Seeking Alpha]
Ardelyx, Inc. (ARDX)
Last ardelyx, inc. earnings: 3/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ardelyx.com/investor-relations
Company Research
Source: Seeking Alpha
In a regulatory filing later Thursday, the maker of the Xphozah kidney disease drug said that despite her resignation, Rodriguez will continue to serve Ardelyx ( ARDX ) in an advisory role through the end of 2024. The departure of Rodriguez, who joined the company as its first commercial chief in 2020, sparked concerns on Wall Street on Friday, with the stock trading lower for the second straight session, albeit on below-average volumes. The resignation is not favorable for the company, and it adds uncertainty. Piper Sandler argued in reaction, adding that it could be related to a strategic disagreement. The firm has an Overweight rating and a $15 target on the stock. Rodriguez's exit comes at a time when Ardelyx ( ARDX ) is waiting to see if there will be any legislative or regulatory action to delay the inclusion of oral-only End Stage Renal Disease-related (ESRD) drugs such as Xphozah into the ESRD Prospective Payment System. If no such action is taken, Xphozah will become
Show less
Read more
Impact Snapshot
Event Time:
ARDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARDX alerts
High impacting Ardelyx, Inc. news events
Weekly update
A roundup of the hottest topics
ARDX
News
- Ardelyx, Inc. (NASDAQ: ARDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Ardelyx, Inc. (NASDAQ: ARDX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Ardelyx, Inc. Reports Employment Inducement GrantsGlobeNewswire
- Ardelyx, Inc. (NASDAQ: ARDX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $15.00 price target on the stock.MarketBeat
- Ardelyx, Inc. (NASDAQ: ARDX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.MarketBeat
ARDX
Earnings
- 5/2/24 - Beat
ARDX
Sec Filings
- 6/21/24 - Form 144
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- ARDX's page on the SEC website